The effect of Pioglitazone in arteriosclerosis obliterans(ASO) patients with type 2 diabetes mellitus or impaired glucose tolerance

The effect of Pioglitazone in arteriosclerosis obliterans(ASO) patients with type 2 diabetes mellitus or impaired glucose tolerance - The effect of Pioglitazone in arteriosclerosis obliterans(ASO) patients with type 2 diabetes mellitus or impaired glucose tolerance

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005057

Enrollment

Registered

2011-02-14

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arteriosclerosis obliterans(ASO) patients with type 2 diabetes mellitus or impaired glucose tolerance

Interventions

Intake of Pioglitazone 30mg once a day. The dosage should be adjusted according to the patient&#39

s symptoms and tolerability by physician&#39

s discretion. Standard treatment. The physician can&#39

t add and change oral blood glucose-lowering drugs and hypoglycemic drugs.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Arteriosclerosis obliterans(ASO) patients with type 2 diabetes mellitus or impaired glucose tolerance

Exclusion criteria

Exclusion criteria: Patients with cardiac failure at present or in the past Patients with severe renal dysfunction Patients with severe liver dysfunction

Design outcomes

Primary

Measure	Time frame
The change of Ankle Brachial Pressure Index(ABI), pulse wave velocity(PWV), Acceleration Time, Wave pattern, pulse wave, adiponectin, blood glucose level, lipid metabolism, blood pressure and BMI at 3month after administration of Pioglitazone	—

Secondary

Measure	Time frame
Statistical involvement of primary outcomes	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026